This is a non-material marketing release. Monitor for actual CDMO customer wins or revenue contributions from Velocity Bioworks in future quarterly filings to assess real commercial traction.
Price Chart
Executive Summary
Valion Bio issued a press release highlighting its wholly owned CDMO subsidiary Velocity Bioworks, positioning its San Antonio facility to capitalize on increased demand for domestic biologics manufacturing following the implementation of Section 232 pharmaceutical tariffs. The filing is a routine marketing/awareness announcement with no financial data, new contracts, or material operational changes.
Key Facts
- Press release dated October 14, 2026, promotes Velocity Bioworks' CDMO capabilities amid new Section 232 tariffs on imported pharmaceuticals (up to 100% on certain products, effective September 29, 2026).
- Velocity Bioworks operates a microbial GMP facility at scales up to 200 liters and maintains mammalian manufacturing capabilities for early-phase biologics.
- No financial figures, new customer contracts, revenue guidance, or material agreements were disclosed.
- The filing contains no earnings data, no changes to the company's pipeline or regulatory status for lead candidate Entolimod.
Financial Impact
No financial impact disclosed; purely promotional/positioning announcement.
Risk Factors
- No disclosed revenue or contracts from Velocity Bioworks — the CDMO may not generate meaningful near-term income.
- Valion remains a clinical-stage biopharma with no approved products; cash burn and dilution risks persist.
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001683168-26-007834 |
| Document: valion_ex9901.htm | 0001683168-26-007834 |
| Document: 0001683168-26-007834-index-headers.html | 0001683168-26-007834 |
| Document: 0001683168-26-007834-index.html | 0001683168-26-007834 |
| Document: 0001683168-26-007834.txt | 0001683168-26-007834 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 8-K | $0.8950 | awaiting T+20 | — | $0.8375 (+6.42%) |
Oct 26, 2026 1d ago | 8-K | $1.15 | awaiting T+20 | — | $0.8375 (−26.91%) |
Oct 22, 2026 5d ago | 8-K | $0.9560 | awaiting T+20 | — | $0.8375 (−12.40%) |
Oct 21, 2026 6d ago | EFFECT | $1.12 | awaiting T+20 | — | $0.8375 (+25.22%) |
Oct 21, 2026 6d ago | EFFECT | $1.12 | awaiting T+20 | — | $0.8375 (+25.22%) |
Oct 16, 2026 10d ago | S-3 | $1.16 | awaiting T+20 | — | $0.8375 (+27.80%) |
Oct 16, 2026 10d ago | DEF 14A | $1.16 | awaiting T+20 | — | $0.8375 (+27.80%) |
Oct 15, 2026 12d ago | 8-K | $1.23 | awaiting T+20 | — | $0.8375 (−31.91%) |
Oct 14, 2026 13d ago | 8-K | $1.45 | awaiting T+20 | — | $0.8375 (−42.24%) |
Oct 8, 2026 19d ago | 8-K | $2.21 | awaiting T+20 | — | $0.8375 (+62.10%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers